The importance of antimicrobial resistance in medical mycology

Neil A.R. Gow; Carolyn Johnson; Judith Berman; Alix T. Coste; Christina A. Cuomo; David S. Perlin; Tihana Bicanic; Thomas S. Harrison; Nathan Wiederhold; Mike Bromley; Tom Chiller; Keegan Edgar

doi:10.1038/s41467-022-32249-5

The importance of antimicrobial resistance in medical mycology

Neil A.R. Gow, Carolyn Johnson, Judith Berman, Alix T. Coste, Christina A. Cuomo, David S. Perlin, Tihana Bicanic, Thomas S. Harrison, Nathan Wiederhold, Mike Bromley, Tom Chiller, Keegan Edgar

Department of Pathology

Resultado de la investigación: Review article › revisión exhaustiva

6 Citas (Scopus)

Resumen

Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health care priority. Some analyses, including the O’Neill report, have predicted that deaths due to drug-resistant bacterial infections may eclipse the total number of cancer deaths by 2050. Although fungal infections remain in the shadow of public awareness, total attributable annual deaths are similar to, or exceeds, global mortalities due to malaria, tuberculosis or HIV. The impact of fungal infections has been exacerbated by the steady rise of antifungal drug resistant strains and species which reflects the widespread use of antifungals for prophylaxis and therapy, and in the case of azole resistance in Aspergillus, has been linked to the widespread agricultural use of antifungals. This review, based on a workshop hosted by the Medical Research Council and the University of Exeter, illuminates the problem of antifungal resistance and suggests how this growing threat might be mitigated.

Idioma original	English (US)
Número de artículo	5352
Publicación	Nature communications
Volumen	13
N.º	1
DOI	https://doi.org/10.1038/s41467-022-32249-5
Estado	Published - dic 2022

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
General
Physics and Astronomy(all)

Acceder al documento

10.1038/s41467-022-32249-5

Otros archivos y enlaces

Citar esto

@article{de48eaed12204b86bed49e60447107fb,

title = "The importance of antimicrobial resistance in medical mycology",

abstract = "Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health care priority. Some analyses, including the O{\textquoteright}Neill report, have predicted that deaths due to drug-resistant bacterial infections may eclipse the total number of cancer deaths by 2050. Although fungal infections remain in the shadow of public awareness, total attributable annual deaths are similar to, or exceeds, global mortalities due to malaria, tuberculosis or HIV. The impact of fungal infections has been exacerbated by the steady rise of antifungal drug resistant strains and species which reflects the widespread use of antifungals for prophylaxis and therapy, and in the case of azole resistance in Aspergillus, has been linked to the widespread agricultural use of antifungals. This review, based on a workshop hosted by the Medical Research Council and the University of Exeter, illuminates the problem of antifungal resistance and suggests how this growing threat might be mitigated.",

author = "Gow, {Neil A.R.} and Carolyn Johnson and Judith Berman and Coste, {Alix T.} and Cuomo, {Christina A.} and Perlin, {David S.} and Tihana Bicanic and Harrison, {Thomas S.} and Nathan Wiederhold and Mike Bromley and Tom Chiller and Keegan Edgar",

note = "Funding Information: N.A.R.G. acknowledges support of Wellcome Senior Investigator (101873/Z/13/Z), and Wellcome Collaborative awards (200208/A/15/Z, 215599/Z/19/Z) and the MRC Centre for Medical Mycology [MR/N006364/2]. J.B. acknowledges funding from the European Research Council (ERC) under the European Union{\textquoteright}s Horizon 2020 research and innovation programme (grant agreement No 951475, ERC SYN FungalTolerance). D.S.P. is supported by NIH grant AI109025. T.B. is the recipient of the Emerging leaders award in Antimicrobial resistance from the Medical research foundation (MRF-160-0009-ELP-BICA-C0802). N.W. has received funding (to UT Health San Antonio) from Astellas, bioMerieux, F2G, Maxwell Biosciences, Sfunga, and the U.S. NIAID/NIH. M.B. receives Wellcome Trust support from collaborative and biomedical resource grants (219551/Z/19/Z, 208396/Z/17/Z), the NIHR Manchester Biomedical Research Centre and F2G. C.A.C. is a fellow in the CIFAR Fungal Kingdom program. Funding Information: N.A.R.G. acknowledges support of Wellcome Senior Investigator (101873/Z/13/Z), and Wellcome Collaborative awards (200208/A/15/Z, 215599/Z/19/Z) and the MRC Centre for Medical Mycology [MR/N006364/2]. J.B. acknowledges funding from the European Research Council (ERC) under the European Union{\textquoteright}s Horizon 2020 research and innovation programme (grant agreement No 951475, ERC SYN FungalTolerance). D.S.P. is supported by NIH grant AI109025. T.B. is the recipient of the Emerging leaders award in Antimicrobial resistance from the Medical research foundation (MRF-160-0009-ELP-BICA-C0802). N.W. has received funding (to UT Health San Antonio) from Astellas, bioMerieux, F2G, Maxwell Biosciences, Sfunga, and the U.S. NIAID/NIH. M.B. receives Wellcome Trust support from collaborative and biomedical resource grants (219551/Z/19/Z, 208396/Z/17/Z), the NIHR Manchester Biomedical Research Centre and F2G. C.A.C. is a fellow in the CIFAR Fungal Kingdom program. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41467-022-32249-5",

language = "English (US)",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - The importance of antimicrobial resistance in medical mycology

AU - Gow, Neil A.R.

AU - Johnson, Carolyn

AU - Berman, Judith

AU - Coste, Alix T.

AU - Cuomo, Christina A.

AU - Perlin, David S.

AU - Bicanic, Tihana

AU - Harrison, Thomas S.

AU - Wiederhold, Nathan

AU - Bromley, Mike

AU - Chiller, Tom

AU - Edgar, Keegan

N1 - Funding Information: N.A.R.G. acknowledges support of Wellcome Senior Investigator (101873/Z/13/Z), and Wellcome Collaborative awards (200208/A/15/Z, 215599/Z/19/Z) and the MRC Centre for Medical Mycology [MR/N006364/2]. J.B. acknowledges funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 951475, ERC SYN FungalTolerance). D.S.P. is supported by NIH grant AI109025. T.B. is the recipient of the Emerging leaders award in Antimicrobial resistance from the Medical research foundation (MRF-160-0009-ELP-BICA-C0802). N.W. has received funding (to UT Health San Antonio) from Astellas, bioMerieux, F2G, Maxwell Biosciences, Sfunga, and the U.S. NIAID/NIH. M.B. receives Wellcome Trust support from collaborative and biomedical resource grants (219551/Z/19/Z, 208396/Z/17/Z), the NIHR Manchester Biomedical Research Centre and F2G. C.A.C. is a fellow in the CIFAR Fungal Kingdom program. Funding Information: N.A.R.G. acknowledges support of Wellcome Senior Investigator (101873/Z/13/Z), and Wellcome Collaborative awards (200208/A/15/Z, 215599/Z/19/Z) and the MRC Centre for Medical Mycology [MR/N006364/2]. J.B. acknowledges funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 951475, ERC SYN FungalTolerance). D.S.P. is supported by NIH grant AI109025. T.B. is the recipient of the Emerging leaders award in Antimicrobial resistance from the Medical research foundation (MRF-160-0009-ELP-BICA-C0802). N.W. has received funding (to UT Health San Antonio) from Astellas, bioMerieux, F2G, Maxwell Biosciences, Sfunga, and the U.S. NIAID/NIH. M.B. receives Wellcome Trust support from collaborative and biomedical resource grants (219551/Z/19/Z, 208396/Z/17/Z), the NIHR Manchester Biomedical Research Centre and F2G. C.A.C. is a fellow in the CIFAR Fungal Kingdom program. Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health care priority. Some analyses, including the O’Neill report, have predicted that deaths due to drug-resistant bacterial infections may eclipse the total number of cancer deaths by 2050. Although fungal infections remain in the shadow of public awareness, total attributable annual deaths are similar to, or exceeds, global mortalities due to malaria, tuberculosis or HIV. The impact of fungal infections has been exacerbated by the steady rise of antifungal drug resistant strains and species which reflects the widespread use of antifungals for prophylaxis and therapy, and in the case of azole resistance in Aspergillus, has been linked to the widespread agricultural use of antifungals. This review, based on a workshop hosted by the Medical Research Council and the University of Exeter, illuminates the problem of antifungal resistance and suggests how this growing threat might be mitigated.

AB - Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health care priority. Some analyses, including the O’Neill report, have predicted that deaths due to drug-resistant bacterial infections may eclipse the total number of cancer deaths by 2050. Although fungal infections remain in the shadow of public awareness, total attributable annual deaths are similar to, or exceeds, global mortalities due to malaria, tuberculosis or HIV. The impact of fungal infections has been exacerbated by the steady rise of antifungal drug resistant strains and species which reflects the widespread use of antifungals for prophylaxis and therapy, and in the case of azole resistance in Aspergillus, has been linked to the widespread agricultural use of antifungals. This review, based on a workshop hosted by the Medical Research Council and the University of Exeter, illuminates the problem of antifungal resistance and suggests how this growing threat might be mitigated.

UR - http://www.scopus.com/inward/record.url?scp=85137738372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137738372&partnerID=8YFLogxK

U2 - 10.1038/s41467-022-32249-5

DO - 10.1038/s41467-022-32249-5

M3 - Review article

C2 - 36097014

AN - SCOPUS:85137738372

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 5352

ER -

The importance of antimicrobial resistance in medical mycology

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto